表紙
市場調査レポート

注入型ドラッグデリバリーの欧州市場 〜2020年:タイプ (デバイス、製剤) ・療法 (ホルモン、腫瘍) ・利用パターン・投与手法・エンドユーザー別の予測

European Injectable Drug Delivery Market by Type (Device, Formulation), Therapeutic (Hormonal, Oncology), Usage Pattern (Curative Care, Immunization), Administration (Skin, Musculoskeletal), End User (Hospital, Home care Setting) - Forecast to 2020

発行 MarketsandMarkets 商品コード 275326
出版日 ページ情報 英文 247 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
注入型ドラッグデリバリーの欧州市場 〜2020年:タイプ (デバイス、製剤) ・療法 (ホルモン、腫瘍) ・利用パターン・投与手法・エンドユーザー別の予測 European Injectable Drug Delivery Market by Type (Device, Formulation), Therapeutic (Hormonal, Oncology), Usage Pattern (Curative Care, Immunization), Administration (Skin, Musculoskeletal), End User (Hospital, Home care Setting) - Forecast to 2020
出版日: 2015年07月28日 ページ情報: 英文 247 Pages
概要

欧州の注入型ドラッグデリバリー (薬物送達) 市場は、2015年における1,147億米ドルの規模から、CAGR (複合年間成長率) 12.6%の伸びで、2020年には2,073億米ドルの規模に達する見込みとなっています。慢性疾患有病率の上昇、生物製剤市場の拡大、自己注射デバイスに対する需要の拡大、ならびに技術的発展などの要因が同市場の成長を促すものと見られています。ドイツは市場が最も急成長することが見込まれており、その高い成長率はインスリン注射および自己注射型デバイスの需要増、特に糖尿病の治療に使われるペン型注射器の需要増によって特徴付けられます。

当レポートでは、欧州の注入型ドラッグデリバリー (薬物送達) 市場を取り上げ、市場の概要、市場発展促進・阻害要因、市場における課題および機会を概括し、タイプ別・適用療法別・利用パターン別・投与手法別・エンドユーザー別・国別に市場の現状と見通しについて調査分析するとともに、競合環境、主要企業のプロファイルをまとめています。

第1章 イントロダクション

  • 調査の目的
  • 市場の定義
  • 市場の範囲
    • 網羅した市場
    • 調査の対象とした年
  • 通貨
  • 制約
  • ステークホルダー

第2章 調査手法

  • 市場規模推定
  • 市場内訳とデータの三角測量
  • 二次情報源からの主要データ
  • 一次情報源からの主要データ
  • 調査の前提条件

第3章 エグゼクティブサマリー

第4章 プレミアムインサイト

  • 欧州の注入型ドラッグデリバリー市場、処方別
  • 欧州の注入型ドラッグデリバリー市場、利用パターン別
  • 欧州の注入型ドラッグデリバリー市場、エンドユーザー別
  • 欧州の注入型ドラッグデリバリー市場、適用療法別

第5章 市場概要

  • イントロダクション
  • 市場区分
    • タイプ別
    • 適用療法別
    • 利用パターン別
    • 投与手法別
    • エンドユーザー別
    • 地域別
  • 市場動態
    • 市場発展促進要因
      • 慢性疾患有病率の上昇
      • 自己注射デバイスに対する需要の拡大
      • 生物製剤市場の拡大
      • 技術的発展
    • 市場発展阻害要因
      • 針刺しによる怪我および感染
      • ドラックデリバリー (薬物送達) 代替手法の出現
    • 市場機会
      • バイオ後続品およびジェネリック注射剤に対する需要の拡大
        • バイオシミラー (バイオ後続品)
        • ジェネリック注射剤
      • 避妊用注射剤
    • 課題
      • 製品の回収
      • 規制のハードル
      • 製品の安定性
      • 注射の滅菌

第6章 欧州の注入型ドラッグデリバリー市場、タイプ別

  • イントロダクション
  • デバイス
    • 従来型注射デバイス
      • 素材別
      • 製品別
      • 可用性別
    • 自己注射デバイス
      • 無針注射器
      • 自己注射器
      • ペン型注射器
      • ウェアラブル注射器
      • その他デバイス
  • 処方
    • 従来型ドラッグデリバリー
      • 溶液
      • 再構成/凍結乾燥製剤
      • 懸濁液
      • 乳濁液
    • 新たなドラッグデリバリー処方
      • コロイド分散
      • 微小粒子
    • 長時間作用型注射製剤

第7章 欧州の注入型ドラッグデリバリー市場、適用療法別

  • イントロダクション
  • 自己免疫疾患
    • 関節リウマチ
    • 多発性硬化症
    • クローン病
    • 乾癬
    • その他の自己免疫疾患
  • ホルモン傷害
    • 糖尿病
    • 貧血
    • 生殖関連疾患
    • 抗血栓/血栓溶解治療
    • 骨粗しょう症
    • 成長ホルモン欠損症 (GHD)
  • 奇病
  • 腫瘍
  • その他
    • 疼痛管理
    • アレルギーの治療
    • エステティック治療
    • C型肝炎
    • 血友病

第8章 欧州の注入型ドラッグデリバリー市場、利用パターン別

  • イントロダクション
  • 治療
  • 予防接種
  • その他 (輸血、血液製剤、避妊薬)

第9章 欧州の注入型ドラッグデリバリー市場、投与手法別

  • イントロダクション
  • 皮膚
  • 循環/筋骨格
  • 臓器
  • 中枢神経系

第10章 欧州の注入型ドラッグデリバリー市場、エンドユーザー別

  • イントロダクション
  • 病院・クリニック
  • 在宅医療の場
  • 調査研究所
  • 製薬およびバイオテクノロジー企業
  • その他のエンドユーザー

第11章 欧州の注入型ドラッグデリバリー市場、国別

  • イントロダクション
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • その他欧州

第12章 競合環境

  • 概要
  • 市場シェア分析
  • 競合状況・動向
    • 新製品発表
    • FDA認可
    • 事業拡張、投資
    • 買収
    • 提携、合意

第13章 企業プロファイル (業績、製品・サービス、主な戦略、最近の動き)

  • イントロダクション
  • BAXTER INTERNATIONAL, INC.
  • BECTON, DICKINSON AND COMPANY
  • GERRESHEIMER AG
  • PFIZER, INC.
  • SCHOTT AG
  • ALKERMES PLC.
  • ELI LILLY AND COMPANY
  • SANDOZ
  • テルモ
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.

第14章 付録

  • 業界専門家の視点
  • 議論のガイド
  • その他の最近の動向
  • 可能なカスタマイゼーション
  • RTの紹介:リアルタイム (RT) 市場情報
  • 関連レポート

図表リスト

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: BT 2073

The European injectable drug delivery market is expected to reach $207.3 billion by 2020 from $114.7 billion in 2015, growing at a CAGR of 12.6% from 2015 to 2020. The market is categorized on the basis of type, therapeutic application, usage pattern, mode of administration, end user, and region. The therapeutic application market is further segmented into autoimmune diseases, hormonal disorders, oncology, orphan diseases, and other therapeutic applications. The oncology segment is expected to witness the highest CAGR in the forecast period.

Factors such as rising incidences of chronic diseases, growth of the biologics market, demand of self-injection devices, and technological advancements, are driving the growth of the European injectable drug delivery market. In addition, Europe is emphasizing on innovation of formulations and improving the delivery of pharmaceuticals. For instance, in November 2012, COMPACT (Collaboration on the Optimization of Macromolecular Pharmaceutical Access to Cellular Targets), a public-private consortium funded by the Innovative Medicines Initiative (IMI), announced the launch of a €30 million ($38.5 million) project, which focuses on improving the delivery of biopharmaceuticals. The consortium would address the major bottlenecks in the development of novel innovative medicines based on biological macromolecules, such as proteins/peptides and oligonucleotides. Such investments are fueling the growth of the market.

Germany is expected to be the fastest-growing country in the European injectable drug delivery market. High growth in this market can be attributed to the increased demand for injectable insulin and self-injection devices, particularly pen injectors which are used in the treatment of diabetes.

Apart from comprehensive geographic and product analysis and market sizing, the report also provides a competitive landscape that covers the growth strategies adopted by industry players over the last three years. In addition, the company profiles comprise basic views on key players in the European injectable drug delivery market and product portfolios, developments, and strategies adopted by market players to maintain and increase their market shares in the near future. The above-mentioned market research data, current market size, and forecast of future trends will help key players and new entrants to make the necessary decisions regarding product offerings, geographical focus, change in strategic approach, R&D investments for innovations in products and technologies, and levels of output in order to remain successful.

Reasons to Buy the Report:

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help firms to garner a greater market share. Firms purchasing the report can use one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on the product portfolios of the top players in the European injectable drug delivery market. The report analyzes this market by type, therapeutic application, usage pattern, mode of administration, end user, and region
  • Product Development/Innovation: Detailed insights on upcoming technologies, R&D activities, and new product launches in the European injectable drug delivery market
  • Competitive Assessment: In-depth assessment of market strategies, geographical and business segments, and product portfolios of leading players in the European injectable drug delivery market
  • Market Development: Comprehensive information about lucrative markets. The report analyzes the market for various European injectable drug delivery across countries
  • Market Diversification: Exhaustive information about new products and services, untapped geographies, recent developments, and investments in the European injectable drug delivery market

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. MARKET SCOPE
    • 1.3.1. MARKETS COVERED
    • 1.3.2. YEARS CONSIDERED FOR THE STUDY
  • 1.4. CURRENCY
  • 1.5. LIMITATIONS
  • 1.6. MARKET STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. MARKET SIZE ESTIMATION
  • 2.2. MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.3. KEY DATA FROM SECONDARY SOURCES
  • 2.4. KEY DATA FROM PRIMARY SOURCES
  • 2.5. ASSUMPTIONS FOR THE STUDY

3. EXECUTIVE SUMMARY

4. PREMIUM INSIGHTS

  • 4.1. EUROPEAN INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION
  • 4.2. EUROPEAN INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN
  • 4.3. EUROPEAN INJECTABLE DRUG DELIVERY MARKET, BY END USER
  • 4.4. EUROPEAN INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET SEGMENTATION
    • 5.2.1. BY TYPE
    • 5.2.2. BY THERAPEUTIC APPLICATION
    • 5.2.3. BY USAGE PATTERN
    • 5.2.4. BY MODE OF ADMINISTRATION
    • 5.2.5. BY END USER
    • 5.2.6. BY REGION
  • 5.3. MARKET DYNAMICS
  • 5.4. DRIVERS
    • 5.4.1. RISING PREVALENCE OF CHRONIC DISEASES
    • 5.4.2. INCREASE IN DEMAND FOR SELF -INJECTION DEVICES
    • 5.4.3. GROWTH OF THE BIOLOGICS MARKET
    • 5.4.4. TECHNOLOGICAL ADVANCEMENTS
  • 5.5. RESTRAINTS
    • 5.5.1. NEEDLESTICK INJURIES AND INFECTIONS
    • 5.5.2. RISE OF ALTERNATE MODE OF DRUG DELIVERY
  • 5.6. OPPORTUNITIES
    • 5.6.1. INCREASE IN DEMAND FOR BIOSIMILARS AND GENERIC INJECTABLES
      • 5.6.1.1. Biosimilars
      • 5.6.1.2. Generic injectables
    • 5.6.2. CONTRACEPTIVE INJECTABLES
  • 5.7. CHALLENGES
    • 5.7.1. PRODUCT RECALL
    • 5.7.2. REGULATORY HURDLES
    • 5.7.3. STABILITY OF THE PRODUCT
    • 5.7.4. STERILITY OF INJECTIONS

6. EUROPEAN INJECTABLE DRUG DELIVERY MARKET, BY TYPE

  • 6.1. INTRODUCTION
  • 6.2. DEVICES
    • 6.2.1. CONVENTIONAL INJECTION DEVICES
      • 6.2.1.1. By Material
        • 6.2.1.1.1. Glass
        • 6.2.1.1.2. Plastic
      • 6.2.1.2. By Product
        • 6.2.1.2.1. Fillable syringes
        • 6.2.1.2.2. Prefilled syringes
      • 6.2.1.3. By Usability
        • 6.2.1.3.1. Reusable syringes
        • 6.2.1.3.2. Disposable syringes
    • 6.2.2. SELF-INJECTION DEVICES
      • 6.2.2.1. Needle-free injectors
        • 6.2.2.1.1. By product
        • 6.2.2.1.1.1. Fillable needle-free injectors
        • 6.2.2.1.1.2. Prefilled needle-free injectors
        • 6.2.2.1.2. By technology
        • 6.2.2.1.2.1. Jet-based needle-free injectors
        • 6.2.2.1.2.2. Spring-based Needle-free injectors
        • 6.2.2.1.2.3. Laser-powered needle-free injectors
        • 6.2.2.1.2.4. Vibration-based needle-free injectors
        • 6.2.2.1.3. By usability
        • 6.2.2.1.3.1. Reusable needle-free injectors
        • 6.2.2.1.3.2. Disposable needle-free injectors
      • 6.2.2.2. Autoinjectors
        • 6.2.2.2.1. By product
        • 6.2.2.2.1.1. Fillable autoinjectors
        • 6.2.2.2.1.2. Prefilled autoinjectors
        • 6.2.2.2.2. By technology
        • 6.2.2.2.2.1. Automated Autoinjectors
        • 6.2.2.2.2.2. Manual Autoinjectors
        • 6.2.2.2.3. By design
        • 6.2.2.2.3.1. Standardized Autoinjectors
        • 6.2.2.2.3.2. Customized Autoinjectors
        • 6.2.2.2.4. By usability
        • 6.2.2.2.4.1. Reusable autoinjectors
        • 6.2.2.2.4.2. Disposable Autoinjectors
      • 6.2.2.3. Pen injectors
        • 6.2.2.3.1. By product
        • 6.2.2.3.1.1. Single-chambered Pen Injectors
        • 6.2.2.3.1.2. Dual-chambered Pen Injectors
        • 6.2.2.3.2. By design
        • 6.2.2.3.2.1. Standard Pen Injectors
        • 6.2.2.3.2.2. Customized Pen Injectors
        • 6.2.2.3.3. By usability
        • 6.2.2.3.3.1. Reusable Pen Injectors
        • 6.2.2.3.3.2. Disposable Pen Injectors
      • 6.2.2.4. Wearable injectors
      • 6.2.2.5. Other Devices
  • 6.3. FORMULATIONS
    • 6.3.1. CONVENTIONAL DRUG DELIVERY
      • 6.3.1.1. SOLUTIONS
      • 6.3.1.2. RECONSTITUTED/LYOPHILIZED FORMULATIONS
      • 6.3.1.3. SUSPENSIONS
      • 6.3.1.4. EMULSIONS
    • 6.3.2. NOVEL DRUG DELIVERY FORMULATIONS
      • 6.3.2.1. COLLOIDAL DISPERSIONS
        • 6.3.2.1.1. LIPOSOMES
        • 6.3.2.1.2. NIOSOMES
        • 6.3.2.1.3. POLYMERIC/MIXED MICELLE
        • 6.3.2.1.4. NANOPARTICLES
        • 6.3.2.1.4.1. NANOSUSPENSIONS
        • 6.3.2.1.4.2. NANOEMULSIONS/MICROEMULSIONS
        • 6.3.2.1.4.3. SOLID-LIPID NANOPARTICLES
      • 6.3.2.2. MICROPARTICLES
        • 6.3.2.2.1. MICROSPHERES
        • 6.3.2.2.2. MICROCAPSULES
    • 6.3.3. LONG-ACTING INJECTION FORMULATIONS

7. EUROPEAN INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION

  • 7.1. INTRODUCTION
  • 7.2. AUTOIMMUNE DISEASES
    • 7.2.1. RHEUMATOID ARTHRITIS
    • 7.2.2. MULTIPLE SCLEROSIS
    • 7.2.3. CROHN'S DISEASE
    • 7.2.4. PSORIASIS
    • 7.2.5. OTHER AUTOIMMUNE DISEASES
  • 7.3. HORMONAL DISORDERS
    • 7.3.1. DIABETES
    • 7.3.2. ANEMIA
    • 7.3.3. REPRODUCTIVE HEALTH DISEASE
    • 7.3.4. ANTITHROMBOTIC/THROMBOLYTIC THERAPY
    • 7.3.5. OSTEOPOROSIS
    • 7.3.6. GROWTH HORMONE DEFICIENCY (GHD)
  • 7.4. ORPHAN DISEASES
  • 7.5. ONCOLOGY
  • 7.6. OTHERS
    • 7.6.1. PAIN MANAGEMENT
    • 7.6.2. ALLERGY TREATMENT
    • 7.6.3. AESTHETIC TREATMENT
    • 7.6.4. HEPATITIS C
    • 7.6.5. HEMOPHILIA

8. EUROPEAN INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN

  • 8.1. INTRODUCTION
  • 8.2. CURATIVE CARE
  • 8.3. IMMUNIZATION
  • 8.4. OTHERS (BLOOD TRANSFUSION AND BLOOD PRODUCTS AND CONTRACEPTIVES)

9. EUROPEAN INJECTABLE DRUG DELIVERY MARKET, BY MODE OF ADMINISTRATION

  • 9.1. INTRODUCTION
  • 9.2. SKIN
  • 9.3. CIRCULATORY/MUSCULOSKELETAL
  • 9.4. ORGANS
  • 9.5. CENTRAL NERVOUS SYSTEM

10. EUROPEAN INJECTABLE DRUG DELIVERY MARKET, BY END USER

  • 10.1. INTRODUCTION
  • 10.2. HOSPITALS AND CLINICS
  • 10.3. HOME CARE SETTINGS
  • 10.4. RESEARCH LABORATORIES
  • 10.5. PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
  • 10.6. OTHER END USERS

11. EUROPEAN INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY

  • 11.1. INTRODUCTION
    • 11.1.1. GERMANY
    • 11.1.2. FRANCE
    • 11.1.3. U.K.
    • 11.1.4. ITALY
    • 11.1.5. SPAIN
    • 11.1.6. REST OF EUROPE (ROE)

12. COMPETITIVE LANDSCAPE

  • 12.1. OVERVIEW
  • 12.2. MARKET SHARE ANALYSIS
  • 12.3. COMPETITIVE SITUATIONS & TRENDS
    • 12.3.1. NEW PRODUCT LAUNCHES
    • 12.3.2. FDA APPROVALS
    • 12.3.3. EXPANSIONS AND INVESTMENTS
    • 12.3.4. ACQUISITIONS
    • 12.3.5. COLLABORATIONS & AGREEMENTS

13. COMPANY PROFILES (Overview, Financials, Products & Services, Strategy, & Developments)*

  • 13.1. INTRODUCTION
  • 13.2. BAXTER INTERNATIONAL, INC.
  • 13.3. BECTON, DICKINSON AND COMPANY
  • 13.4. GERRESHEIMER AG
  • 13.5. PFIZER, INC.
  • 13.6. SCHOTT AG
  • 13.7. ALKERMES PLC.
  • 13.8. ELI LILLY AND COMPANY
  • 13.9. SANDOZ
  • 13.10. TERUMO CORPORATION
  • 13.11. TEVA PHARMACEUTICAL INDUSTRIES LTD.

*Details on Financials, Product & Services, Strategy, & Developments might not be captured in case of unlisted companies.

14. APPENDIX

  • 14.1. INSIGHTS FROM INDUSTRY EXPERTS
  • 14.2. DISCUSSION GUIDE
  • 14.3. OTHER RECENT DEVELOPMENTS
  • 14.4. AVAILABLE CUSTOMIZATIONS
  • 14.5. RT: REAL-TIME MARKET INTELLIGENCE
  • 14.6. RELATED REPORTS

LIST OF TABLES

  • TABLE 1: INCREASE IN DEMAND FOR SELF-INJECTION DEVICES IS BOOSTING THE MARKET GROWTH
  • TABLE 2: NEEDLESTICK INJURIES AND INFECTIONS ARE RESTRAINING THE MARKET GROWTH
  • TABLE 3: INCREASE IN DEMAND OF BIOSIMILARS OFFERS AN ARRAY OF OPPORTUNITIES FOR THE MARKET
  • TABLE 4: PRODUCT RECALL POSE SIGNIFICANT CHALLENGES TO MARKET GROWTH
  • TABLE 5: EUROPE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 6: EUROPE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 7: EUROPE: INJECTABLE DRUG DELIVERY DEVICES MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 8: EUROPE: INJECTABLE DRUG DELIVERY DEVICES MARKET SIZE, BY TYPE, 2013-2020 (MILLION UNITS)
  • TABLE 9: EUROPE: INJECTABLE DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 10: EUROPE: INJECTABLE DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2013-2020 (MILLION UNITS)
  • TABLE 11: EUROPE: CONVENTIONAL INJECTION DEVICES MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 12: EUROPE: CONVENTIONAL INJECTION DEVICES MARKET SIZE, BY COUNTRY, 2013-2020 (MILLION UNITS)
  • TABLE 13: EUROPE: CONVENTIONAL INJECTION DEVICES MARKET SIZE, BY MATERIAL, 2013-2020 ($MILLION)
  • TABLE 14: EUROPE: CONVENTIONAL INJECTION DEVICES MARKET SIZE, BY MATERIAL, 2013-2020 (MILLION UNITS)
  • TABLE 15: EUROPE: CONVENTIONAL GLASS INJECTION DEVICES MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 16: EUROPE: CONVENTIONAL GLASS INJECTION DEVICES MARKET SIZE, BY COUNTRY, 2013-2020 (MILLION UNITS)
  • TABLE 17: EUROPE: CONVENTIONAL PLASTIC INJECTION DEVICES MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 18: EUROPE: CONVENTIONAL PLASTIC INJECTION DEVICES MARKET SIZE, BY COUNTRY, 2013-2020 (MILLION UNITS)
  • TABLE 19: EUROPE: CONVENTIONAL INJECTION DEVICES MARKET SIZE, BY PRODUCT, 2013-2020 ($MILLION)
  • TABLE 20: EUROPE: CONVENTIONAL INJECTION DEVICES MARKET SIZE, BY PRODUCT, 2013-2020 (MILLION UNITS)
  • TABLE 21: EUROPE: CONVENTIONAL FILLABLE INJECTION DEVICES MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 22: EUROPE: CONVENTIONAL FILLABLE INJECTION DEVICES MARKET SIZE, BY COUNTRY, 2013-2020 (MILLION UNITS)
  • TABLE 23: EUROPE: CONVENTIONAL PREFILLED INJECTION DEVICES MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 24: EUROPE: CONVENTIONAL PREFILLED INJECTION DEVICES MARKET SIZE, BY COUNTRY, 2013-2020 (MILLION UNITS)
  • TABLE 25: EUROPE: CONVENTIONAL INJECTION DEVICES MARKET SIZE, BY USABILITY, 2013-2020 ($MILLION)
  • TABLE 26: EUROPE: CONVENTIONAL INJECTION DEVICES MARKET SIZE, BY USABILITY, 2013-2020 (MILLION UNITS)
  • TABLE 27: EUROPE: CONVENTIONAL REUSABLE INJECTION DEVICES MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 28: EUROPE: CONVENTIONAL REUSABLE INJECTION DEVICES MARKET SIZE, BY COUNTRY, 2013-2020 (MILLION UNITS)
  • TABLE 29: EUROPE: CONVENTIONAL DISPOSABLE INJECTION DEVICES MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 30: EUROPE: CONVENTIONAL DISPOSABLE INJECTION DEVICES MARKET SIZE, BY COUNTRY, 2013-2020 (MILLION UNITS)
  • TABLE 31: EUROPE: SELF-INJECTION DEVICES MARKET, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 32: EUROPE: SELF-INJECTION DEVICES MARKET, BY TYPE, 2013-2020 (MILLION UNITS)
  • TABLE 33: EUROPE: SELF-INJECTION DEVICES MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 34: EUROPE: SELF-INJECTION DEVICES MARKET SIZE, BY COUNTRY, 2013-2020 (MILLION UNITS)
  • TABLE 35: EUROPE: NEEDLE-FREE INJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 36: EUROPE: NEEDLE-FREE INJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 (MILLION UNITS)
  • TABLE 37: EUROPE: NEEDLE-FREE INJECTORS MARKET SIZE, BY PRODUCT, 2013-2020 ($MILLION)
  • TABLE 38: EUROPE: NEEDLE-FREE INJECTORS MARKET SIZE, BY PRODUCT, 2013-2020 (MILLION UNITS)
  • TABLE 39: EUROPE: FILLABLE NEEDLE-FREE INJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 40: EUROPE: FILLABLE NEEDLE-FREE INJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 (MILLION UNITS)
  • TABLE 41: EUROPE: PREFILLED NEEDLE-FREE INJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 42: EUROPE: PREFILLED NEEDLE-FREE INJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 (MILLION UNITS)
  • TABLE 43: EUROPE: NEEDLE-FREE INJECTORS MARKET SIZE, BY TECHNOLOGY, 2013-2020 ($MILLION)
  • TABLE 44: EUROPE: NEEDLE-FREE INJECTORS MARKET SIZE, BY TECHNOLOGY, 2013-2020 (MILLION UNITS)
  • TABLE 45: EUROPE: JET-BASED NEEDLE-FREE INJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 46: EUROPE: JET-BASED NEEDLE-FREE INJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 (MILLION UNITS)
  • TABLE 47: EUROPE: SPRING-BASED NEEDLE-FREE INJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 48: EUROPE: SPRING-BASED NEEDLE-FREE INJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 (MILLION UNITS)
  • TABLE 49: EUROPE: LASER-POWERED NEEDLE-FREE INJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 50: EUROPE: LASER-POWERED NEEDLE-FREE INJECTORS MARKET, BY COUNTRY, 2013-2020 (MILLION UNITS)
  • TABLE 51: EUROPE: VIBRATION-BASED NEEDLE-FREE INJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 52: EUROPE: VIBRATION-BASED NEEDLE-FREE INJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 (MILLION UNITS)
  • TABLE 53: EUROPE: NEEDLE-FREE INJECTORS MARKET SIZE, BY USABILITY, 2013-2020 ($MILLION)
  • TABLE 54: EUROPE: NEEDLE-FREE INJECTORS MARKET SIZE, BY USABILITY, 2013-2020 (MILLION UNITS)
  • TABLE 55: EUROPE: REUSABLE NEEDLE-FREE INJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 56: EUROPE: REUSABLE NEEDLE-FREE INJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 (MILLION UNITS)
  • TABLE 57: EUROPE: DISPOSABLE NEEDLE-FREE INJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 58: EUROPE: DISPOSABLE NEEDLE-FREE INJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 (MILLION UNITS)
  • TABLE 59: EUROPE: AUTOINJECTOR DEVICES MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 60: EUROPE: AUTOINJECTOR DEVICES MARKET SIZE, BY COUNTRY, 2013-2020 (MILLION UNITS)
  • TABLE 61: EUROPE: AUTOINJECTOR DEVICES MARKET SIZE, BY PRODUCT, 2013-2020 ($MILLION)
  • TABLE 62: EUROPE: AUTOINJECTOR DEVICES MARKET SIZE, BY PRODUCT, 2013-2020 (MILLION UNITS)
  • TABLE 63: EUROPE: FILLABLE AUTOINJECTOR DEVICES MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 64: EUROPE: FILLABLE AUTOINJECTOR DEVICES MARKET SIZE, BY COUNTRY, 2013-2020 (MILLION UNITS)
  • TABLE 65: EUROPE: PREFILLED AUTOINJECTOR DEVICES MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 66: EUROPE: PREFILLED AUTOINJECTOR DEVICES MARKET SIZE, BY COUNTRY, 2013-2020 (MILLION UNITS)
  • TABLE 67: EUROPE: AUTOINJECTOR DEVICES MARKET SIZE, BY TECHNOLOGY, 2013-2020 ($MILLION)
  • TABLE 68: EUROPE: AUTOINJECTOR DEVICES MARKET SIZE, BY TECHNOLOGY, 2013-2020 (MILLION UNITS)
  • TABLE 69: EUROPE: AUTOMATED AUTOINJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 70: EUROPE: AUTOMATED AUTOINJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 (MILLION UNITS)
  • TABLE 71: EUROPE: MANUAL AUTOINJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 72: EUROPE: MANUAL AUTOINJECTORS MARKET, BY COUNTRY, 2013-2020 (MILLION UNITS)
  • TABLE 73: EUROPE: AUTOINJECTORS MARKET SIZE, BY DESIGN, 2013-2020 ($MILLION)
  • TABLE 74: EUROPE: AUTOINJECTORS MARKET SIZE, BY DESIGN, 2013-2020 (MILLION UNITS)
  • TABLE 75: EUROPE: STANDARDIZED AUTOINJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 76: EUROPE: STANDARDIZED AUTOINJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 (MILLION UNITS)
  • TABLE 77: EUROPE: CUSTOMIZED AUTOINJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 78: EUROPE: CUSTOMIZED AUTOINJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 (MILLION UNITS)
  • TABLE 79: EUROPE: AUTOINJECTOR MARKET SIZE, BY USABILITY, 2013-2020 ($MILLION)
  • TABLE 80: EUROPE: AUTOINJECTORS MARKET SIZE, BY USABILITY, 2013-2020 (MILLION UNITS)
  • TABLE 81: EUROPE: REUSABLE AUTOINJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 82: EUROPE: REUSABLE AUTOINJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 (MILLION UNITS)
  • TABLE 83: EUROPE: DISPOSABLE AUTOINJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 84: EUROPE: DISPOSABLE AUTOINJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 (MILLION UNITS)
  • TABLE 85: EUROPE: PEN INJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 86: EUROPE: PEN INJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 (MILLION UNITS)
  • TABLE 87: EUROPE: PEN INJECTORS MARKET SIZE, BY PRODUCT, 2013-2020 ($MILLION)
  • TABLE 88: EUROPE: PEN INJECTORS MARKET SIZE, BY PRODUCT, 2013-2020 (MILLION UNITS)
  • TABLE 89: EUROPE: SINGLE-CHAMBERED PEN INJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 90: EUROPE: SINGLE-CHAMBERED PEN INJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 (MILLION UNITS)
  • TABLE 91: EUROPE: DUAL-CHAMBERED PEN INJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 92: EUROPE: DUAL-CHAMBERED PEN INJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 (MILLION UNITS)
  • TABLE 93: EUROPE: PEN INJECTORS MARKET SIZE, BY DESIGN, 2013-2020 ($MILLION)
  • TABLE 94: EUROPE: PEN INJECTORS MARKET SIZE, BY DESIGN, 2013-2020 (MILLION UNITS)
  • TABLE 95: EUROPE: STANDARD PEN INJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 96: EUROPE: STANDARD PEN INJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 (MILLION UNITS)
  • TABLE 97: EUROPE: CUSTOMIZED PEN INJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 98: EUROPE: CUSTOMIZED PEN INJECTORS MARKET, BY COUNTRY, 2013-2020 (MILLION UNITS)
  • TABLE 99: EUROPE: PEN INJECTOR MARKET SIZE, BY USABILITY, 2013-2020 ($MILLION)
  • TABLE 100: EUROPE: PEN INJECTORS MARKET SIZE, BY USABILITY, 2013-2020 (MILLION UNITS)
  • TABLE 101: EUROPE: REUSABLE PEN INJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 102: EUROPE: REUSABLE PEN INJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 (MILLION UNITS)
  • TABLE 103: EUROPE: DISPOSABLE PEN INJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 104: EUROPE: DISPOSABLE PEN INJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 (MILLION UNITS)
  • TABLE 105: EUROPE: WEARABLE INJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 106: EUROPE: WEARABLE INJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 (MILLION UNITS)
  • TABLE 107: EUROPE: OTHER DEVICES MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 108: EUROPE: OTHER DEVICES MARKET SIZE, BY COUNTRY, 2013-2020 (MILLION UNITS)
  • TABLE 109: EUROPE: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 110: EUROPE: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 111: EUROPE: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 112: EUROPE: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 113: EUROPE: SOLUTIONS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 114: EUROPE: RECONSTITUTED/LYOPHILIZED FORMULATIONS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 115: EUROPE: SUSPENSIONS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 116: EUROPE: EMULSION MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 117: EUROPE: NOVEL DRUG DELIVERY FORMULATIONS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 118: EUROPE: NOVEL DRUG DELIVERY FORMULATIONS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 119: EUROPE: COLLOIDAL DISPERSION MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 120: EUROPE: COLLOIDAL DISPERSION MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 121: EUROPE: LIPOSOMES MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 122: EUROPE: NIOSOMES MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 123: EUROPE: POLYMERIC/MIXED MICELLES MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 124: EUROPE: NANOPARTICLES MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 125: EUROPE: NANOPARTICLES MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 126: EUROPE: NANOSUSPENSIONS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 127: EUROPE: NANOEMULSIONS/MICROEMULSIONS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 128: EUROPE: SOLID-LIPID NANOPARTICLES MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 129: EUROPE: MICROPARTICLES MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 130: EUROPE: MICROPARTICLES MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 131: EUROPE: MICROSPHERES MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 132: EUROPE: MICROCAPSULES MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 133: EUROPE: LONG-ACTING INJECTION FORMULATIONS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 134: EUROPE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2013 - 2020 ($MILLION)
  • TABLE 135: EUROPE: INJECTABLE DRUG DELIVERY THERAPEUTIC APPLICATIONS MARKET SIZE, BY COUNTRY, 2013 - 2020 ($MILLION)
  • TABLE 136: EUROPE: AUTOIMMUNE DISEASES MARKET SIZE, BY INDICATION, 2013-2020 ($MILLION)
  • TABLE 137: EUROPE: AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 138: EUROPE: RHEUMATOID ARTHRITIS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 139: EUROPE: MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 140: EUROPE: CROHN'S DISEASE MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 141: EUROPE: PSORIASIS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 142: EUROPE: OTHER AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 143: EUROPE: HORMONAL DISORDERS MARKET SIZE, BY INDICATION, 2013-2020 ($MILLION)
  • TABLE 144: EUROPE: HORMONAL DISORDERS MARKET SIZE, BY COUNTRY, 2013 -2020 ($MILLION)
  • TABLE 145: EUROPE: DIABETES MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 146: EUROPE: ANEMIA MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 147: EUROPE: REPRODUCTIVE HEALTH DISEASE MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 148: EUROPE: ANTITHROMBOTIC/THROMBOLYTIC THERAPY MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 149: EUROPE: OSTEOPOROSIS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 150: EUROPE: GROWTH HORMONE DEFICIENCY (GHD) MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 151: EUROPE: ORPHAN DISEASES MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 152: EUROPE: ONCOLOGY MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 153: EUROPE: OTHER THERAPEUTIC APPLICATIONS MARKET SIZE, BY INDICATION, 2013-2020 ($MILLION)
  • TABLE 154: EUROPE: OTHER THERAPEUTIC APPLICATIONS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 155: EUROPE: PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 156: EUROPE: ALLERGY MANAGEMENT MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 157: EUROPE: AESTHETIC TREATMENT MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 158: EUROPE: HEPATITIS C MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 159: EUROPE: HEMOPHILIA MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 160: EUROPE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY USAGE PATTERN, 2013 - 2020 ($MILLION)
  • TABLE 161: EUROPE: USAGE PATTERN MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 162: EUROPE: CURATIVE CARE MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 163: EUROPE: IMMUNIZATION MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 164: EUROPE: OTHER USAGE PATTERNS MARKET SIZE, BY COUNTRY, 2013 - 2020 ($MILLION)
  • TABLE 165: EUROPE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY MODE OF ADMINISTRATION, 2013 - 2020 ($MILLION)
  • TABLE 166: EUROPE: MODE OF ADMINISTRATION MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 167: EUROPE: SKIN ADMINISTRATION MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 168: EUROPE: CIRCULATORY/MUSCULOSKELETAL ADMINISTRATION MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 169: EUROPE: ORGAN ADMINISTRATION MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 170: EUROPE: CENTRAL NERVOUS SYSTEM ADMINISTRATION, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 171: EUROPE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY END USER, 2013-2020 ($MILLION)
  • TABLE 172: EUROPE: END USER MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 173: EUROPE: HOSPITALS AND CLINICS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 174: EUROPE: HOME CARE SETTING MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 175: EUROPE: RESEARCH LABORATORIES MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 176: EUROPE: PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 177: EUROPE: OTHER END USERS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 178: GERMANY: INJECTABLE DRUG DELIVERY MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 179: GERMANY: INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE, 2013-2020 ($MILLION)
  • TABLE 180: GERMANY: INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE, 2013-2020 (MILLION UNITS)
  • TABLE 181: GERMANY: INJECTABLE DRUG DELIVERY MARKET SIZE, BY FORMULATION, 2013-2020 ($MILLION)
  • TABLE 182: GERMANY: INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2013-2020 ($MILLION)
  • TABLE 183: GERMANY: INJECTABLE DRUG DELIVERY MARKET SIZE, BY USAGE PATTERN, 2013-2020 ($MILLION)
  • TABLE 184: GERMANY: INJECTABLE DRUG DELIVERY MARKET SIZE, BY MODE OF ADMINISTRATION, 2013-2020 ($MILLION)
  • TABLE 185: GERMANY: INJECTABLE DRUG DELIVERY MARKET SIZE, BY END USER, 2013-2020 ($MILLION)
  • TABLE 186: FRANCE :INJECTABLE DRUG DELIVERY MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 187: FRANCE :INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE, 2013 - 2020 ($MILLION)
  • TABLE 188: FRANCE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE, 2013 - 2020 (MILLION UNITS)
  • TABLE 189: FRANCE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY FORMULATION, 2013-2020 ($MILLION)
  • TABLE 190: FRANCE: INJECTABLE DRUG DELIVERY MARKET SIZE , BY THERAPEUTIC APPLICATION, 2013-2020 ($MILLION)
  • TABLE 191: FRANCE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY USAGE PATTERN, 2013-2020 ($MILLION)
  • TABLE 192: FRANCE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY MODE OF ADMINISTRATION, 2013-2020 ($MILLION)
  • TABLE 193: FRANCE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY END USER, 2013-2020 ($MILLION)
  • TABLE 194: U.K.: INJECTABLE DRUG DELIVERY MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 195: U.K.: INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE, 2013 - 2020 ($MILLION)
  • TABLE 196: U.K.: INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE, 2013-2020 (MILLION UNITS)
  • TABLE 197: U.K.: INJECTABLE DRUG DELIVERY MARKET SIZE, BY FORMULATION, 2013-2020 ($MILLION)
  • TABLE 198: U.K.: INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2013-2020 ($MILLION)
  • TABLE 199: U.K.: INJECTABLE DRUG DELIVERY MARKET SIZE, BY USAGE PATTERN, 2013-2020 ($MILLION)
  • TABLE 200: U.K.: INJECTABLE DRUG DELIVERY MARKET SIZE, BY MODE OF ADMINISTRATION, 2013-2020 ($MILLION)
  • TABLE 201: U.K.: INJECTABLE DRUG DELIVERY MARKET SIZE, BY END USER, 2013-2020 ($MILLION)
  • TABLE 202: ITALY: INJECTABLE DRUG DELIVERY MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 203: ITALY: INJECTABLE DRUG DELIVERY MARKET SIZE , BY DEVICE, 2013-2020 ($MILLION)
  • TABLE 204: ITALY: INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE, 2013-2020 (MILLION UNITS)
  • TABLE 205: ITALY: INJECTABLE DRUG DELIVERY MARKET SIZE, BY FORMULATION, 2013-2020 ($MILLION)
  • TABLE 206: ITALY: INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2013-2020 ($MILLION)
  • TABLE 207: ITALY: INJECTABLE DRUG DELIVERY MARKET SIZE, BY USAGE PATTERN, 2013-2020 ($MILLION)
  • TABLE 208: ITALY: INJECTABLE DRUG DELIVERY MARKET SIZE, BY MODE OF ADMINISTRATION, 2013-2020 ($MILLION)
  • TABLE 209: ITALY: INJECTABLE DRUG DELIVERY MARKET SIZE, BY END USER, 2013-2020 ($MILLION)
  • TABLE 210: SPAIN: INJECTABLE DRUG DELIVERY MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 211: SPAIN: INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE, 2013-2020 ($MILLION)
  • TABLE 212: SPAIN: INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE, 2013-2020 (MILLION UNITS)
  • TABLE 213: SPAIN: INJECTABLE DRUG DELIVERY MARKET SIZE , BY FORMULATION, 2013-2020 ($MILLION)
  • TABLE 214: SPAIN: INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2013-2020 ($MILLION)
  • TABLE 215: SPAIN: INJECTABLE DRUG DELIVERY MARKET SIZE, BY USAGE PATTERN, 2013-2020 ($MILLION)
  • TABLE 216: SPAIN: INJECTABLE DRUG DELIVERY MARKET SIZE, BY MODE OF ADMINISTRATION, 2013-2020 ($MILLION)
  • TABLE 217: SPAIN: INJECTABLE DRUG DELIVERY MARKET SIZE, BY END USER, 2013-2020 ($MILLION)
  • TABLE 218: ROE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 219: ROE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE, 2013-2020 ($MILLION)
  • TABLE 220: ROE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE, 2013-2020 (MILLION UNITS)
  • TABLE 221: ROE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY FORMULATION, 2013-2020 ($MILLION)
  • TABLE 222: ROE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2013-2020 ($MILLION)
  • TABLE 223: ROE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY USAGE PATTERN, 2013-2020 ($MILLION)
  • TABLE 224: ROE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY MODE OF ADMINISTRATION, 2013-2020 ($MILLION)
  • TABLE 225: ROE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY END USER, 2013-2020 ($MILLION)
  • TABLE 226: NEW PRODUCT LAUNCHES (2012-2015)
  • TABLE 227: FDA APPROVALS (2012-2015)
  • TABLE 228: EXPANSIONS AND INVESTMENTS (2012-2015)
  • TABLE 229: ACQUISITIONS (2012-2015)
  • TABLE 230: COLLABORATIONS & AGREEMENTS (2012-2015)

LIST OF FIGURES

  • FIGURE 1: RESEARCH DESIGN
  • FIGURE 2: MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
  • FIGURE 3: MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
  • FIGURE 4: BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE AND DESIGNATION
  • FIGURE 5: DATA TRIANGULATION METHODOLOGY
  • FIGURE 6: EUROPEAN INJECTABLE DRUG DELIVERY MARKET SNAPSHOT, BY FORMULATION (2015 VS. 2020)
  • FIGURE 7: EUROPEAN INJECTABLE DRUG DELIVERY MARKET, BY DEVICES (2015-2020): SELF-INJECTION DEVICES TO WITNESS HIGHEST GROWTH RATE
  • FIGURE 8: HOSPITALS/CLINICS FORM THE LARGEST END-USER SEGMENT IN 2014
  • FIGURE 9: EUROPEAN INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION (2015-2020): HORMONAL DISORDERS SEGMENT DOMINATES MARKET
  • FIGURE 10: EUROPEAN INJECTABLE DRUG DELIVERY FORMULATIONS MARKET TO GROW AT THE HIGHEST CAGR FROM 2015 TO 2020
  • FIGURE 11: THE CURATIVE CARE SEGMENT TO WITNESS THE HIGHEST GROWTH RATE IN THE FORECAST PERIOD
  • FIGURE 12: HOME CARE SETTINGS SEGMENT TO ACCOUNT FOR THE LARGEST SHARE IN 2015
  • FIGURE 13: HORMONAL DISORDERS SEGMENT TO ACCOUNT FOR THE LARGEST SHARE OF THE MARKET IN 2015
  • FIGURE 14: INJECTABLE DRUG DELIVERY MARKET SEGMENTATION, BY TYPE
  • FIGURE 15: INJECTABLE DRUG DELIVERY MARKET SEGMENTATION, BY THERAPEUTIC APPLICATION
  • FIGURE 16: INJECTABLE DRUG DELIVERY MARKET SEGMENTATION, BY USAGE PATTERN
  • FIGURE 17: INJECTABLE DRUG DELIVERY MARKET SEGMENTATION, BY MODE OF ADMINISTRATION
  • FIGURE 18: INJECTABLE DRUG DELIVERY MARKET SEGMENTATION, BY END USER
  • FIGURE 19: INJECTABLE DRUG DELIVERY MARKET SEGMENTATION, BY REGION
  • FIGURE 20: RISING PREVALENCE OF CHRONIC DISEASES POPULATION WILL DRIVE THE MARKET GROWTH
  • FIGURE 21: EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2013 - 2020 ($MILLION)
  • FIGURE 22: THERAPEUTIC APPLICATIONS: GERMANY TO SHOW HIGHEST GROWTH
  • FIGURE 23: EUROPEAN INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN: CURATIVE CARE TO HOLD LARGEST SHARE
  • FIGURE 24: EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY MODE OF ADMINISTRATION: SKIN SEGMENT TO SHOW HIGHEST GROWTH
  • FIGURE 25: EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY END USER
  • FIGURE 26: EUROPE: EUROPEAN INJECTABLE DRUG DELIVERY MARKET, BY END USER: HOSPITALS/CLINICS TO HOLD LARGEST SHARE
  • FIGURE 27: EUROPE: FORMULATIONS MARKET SNAPSHOT
  • FIGURE 28: ROE: SELF-INJECTION DEVICES MARKET SNAPSHOT
  • FIGURE 29: KEY PLAYERS ADOPTED ORGANIC GROWTH STRATEGIES BETWEEN 2012 & 2015
  • FIGURE 30: GLOBAL INJECTABLE DRUG DELIVERY MARKET SHARE, BY KEY PLAYER (2014)
  • FIGURE 31: MARKET EVOLUTION FRAMEWORK: PARTNERSHIPS, AGREEMENTS AND COLLABORATIONS, & EXPANSIONS ARE FUELING MARKET GROWTH ,2014 &2015
  • FIGURE 32: BATTLE FOR MARKET SHARE: NEW PRODUCT LAUNCHES WAS THE KEY STRATEGY LEADING PLAYERS FOLLOWED, 2013
  • FIGURE 33: PRODUCT BENCHMARKING FOR TOP 5 PLAYERS
  • FIGURE 34: BAXTER INTERNATIONAL, INC.: COMPANY SNAPSHOT
  • FIGURE 35: BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT
  • FIGURE 36: GERRESHEIMER AG: COMPANY SNAPSHOT
  • FIGURE 37: PFIZER, INC.: COMPANY SNAPSHOT
  • FIGURE 38: SCHOTT AG: COMPANY SNAPSHOT
  • FIGURE 39: ALKERMES PLC: COMPANY SNAPSHOT
  • FIGURE 40: ELI LILLY AND COMPANY: COMPANY SNAPSHOT
  • FIGURE 41: SANDOZ: COMPANY SNAPSHOT
  • FIGURE 42: TERUMO CORPORATION: COMPANY SNAPSHOT
  • FIGURE 43: TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
Back to Top